| Click on "►" to expand:|
 BRAND NAMES
 MECHANISM OF ACTION
Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.
Abciximab is indicated as an adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications due to the procedure:
- In patients undergoing percutaneous coronary intervention
- In patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours
The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 µg/kg/min (to a maximum of 10 µg/min) for 12 hours.
Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25 mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 µg/min, concluding one hour after the PCI.
- Active internal bleeding
- Recent (within 6 weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance
- History of cerebrovascular accident (CVA) within 2 years, or CVA with a significant residual neurological deficit
- Bleeding diathesis
- Administration of oral anticoagulants within 7 days unless prothrombin time ≤1.2 times control
- Thrombocytopenia (<100,000 cells/μL)
- Recent (within 6 weeks) major surgery or trauma
- Intracranial neoplasm, arteriovenous malformation, or aneurysm
- Severe uncontrolled hypertension
- Presumed or documented history of vasculitis
- Use of intravenous dextran before percutaneous coronary intervention, or intent to use it during intervention
- Known hypersensitivity to any component of this product or to murine proteins
 PREGNANCY AND LACTATION
 SIDE EFFECTS
- Increased risk of bleeding
- Abciximab may result in the formation of human anti-chimeric antibodies (HACA) that could potentially cause allergic or hypersensitivity reactions (including anaphylaxis), thrombocytopenia, or diminished benefit upon readministration.